BCDA — BioCardia, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 925741 ·
Last close
$0.79
Market Cap
$11.93M
52W High
$1.80
52W Low
$0.66
ADV30
117,206
Next earnings
—
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -1,835,000 -1,817,000 3,071,000 2,224,000 2,236,000
Jun 2026 — — — — — — —
Mar 2026 0 — -2,266,000 -2,259,000 1,712,000 951,000 2,778,000
Dec 2025 0 — -2,013,000 -1,984,000 3,413,000 2,496,000 2,518,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,477,000
Investing CF
$-10,000
Financing CF
$7,489,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-170,608,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-7,818,000
Pretax Income TTM
$-7,775,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -8,278,000 -8,228,000 3,413,000 2,518,000 895,000 -7,436,000
Dec 2024 58,000 -8,001,000 -7,946,000 3,724,000 2,887,000 837,000 -7,886,000
Dec 2023 477,000 -11,644,000 -11,571,000 2,987,000 4,590,000 -1,603,000 -9,974,000
Dec 2022 1,352,000 -11,901,000 -11,907,000 9,793,000 4,901,000 4,892,000 -10,561,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$4,005,000
NetIncome TTM
$-7,339,000
OpCashFlow TTM
—
Assets (Latest)
$4,755,000
Forward EPS
$-0.48

Peers — same industry

TickerNameMarket CapLastDaily %
ATYR aTYR PHARMA INC $12.47M $4.99 —
DYAI DYADIC INTERNATIONAL INC $12.66M $0.32 —
GRML Greenland Mines Ltd $10.87M $3.42 —
PASG Passage BIO, Inc. $13.58M $4.22 —
PLUR Pluri Inc. $14.09M $0.98 —

News headlines (Yahoo Finance, 1h cache)

BioCardia (BCDA) Upgraded to Buy: Here's What You Should Know
2026-11-17 16:00 · Yahoo
BioCardia, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
BioCardia (BCDA) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances as ...
2026-11-13 05:05 · Yahoo
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
2026-11-12 21:19 · Yahoo
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
2026-11-09 21:18 · Yahoo
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
2026-11-06 13:30 · Yahoo
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
2026-10-19 13:15 · Yahoo
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
2026-10-07 13:00 · Yahoo
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
2026-10-01 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.